Episode Details
Back to EpisodesAmerican Society of Hematology Annual Meeting 2024 – Updates in CLL (Part 2)
Episode 451
Published 1 year, 7 months ago
Description
Drs. Coombs and Shadman review CLL abstracts presented at the ASH 2024 annual meeting, including results from 2 early‑phase evaluations of BTK degraders and primary results of the ibrutinib combination cohort from the TRANSCEND CLL 004 study of the CAR T‑cell therapeutic, liso‑cel.